scholarly article | Q13442814 |
P356 | DOI | 10.1002/AJH.23546 |
P698 | PubMed publication ID | 23861234 |
P50 | author | Gianpietro Semenzato | Q42574068 |
Livio Trentin | Q56383785 | ||
Francesco Zaja | Q57307002 | ||
Renato Fani | Q61307102 | ||
Francesco Rodeghiero | Q87875711 | ||
Rossella Paolini | Q89761693 | ||
Miriam Isola | Q102150006 | ||
P2093 | author name string | Carlo Visco | |
Stefano Volpetti | |||
Achille Ambrosetti | |||
Michael Mian | |||
Giovanni Pizzolo | |||
Sergio Cortelazzo | |||
Paolo Vivaldi | |||
Rosaria Sancetta | |||
Ilaria Nichele | |||
Monica Castelli | |||
Simona Puglisi | |||
Cinzia Sissa | |||
P2860 | cites work | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up | Q27851444 | ||
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia | Q27851685 | ||
Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Q28394721 | ||
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness | Q29013141 | ||
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma | Q33366403 | ||
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia | Q33377308 | ||
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma | Q33380352 | ||
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients | Q33390369 | ||
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33396737 | ||
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33402713 | ||
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia | Q33406164 | ||
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
The clinical and epidemiological burden of chronic lymphocytic leukaemia | Q35804467 | ||
Treatment of elderly patients with chronic lymphocytic leukemia | Q37386705 | ||
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia | Q37634897 | ||
Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines | Q39359493 | ||
Bendamustine-associated hemolytic anemia | Q43266151 | ||
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. | Q52621343 | ||
P433 | issue | 11 | |
P921 | main subject | bendamustine | Q425745 |
lymphocyte | Q715347 | ||
chronic lymphocytic leukemia | Q1088156 | ||
P304 | page(s) | 955-960 | |
P577 | publication date | 2013-09-09 | |
P1433 | published in | American Journal of Hematology | Q4744246 |
P1476 | title | Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice | |
P478 | volume | 88 |
Q35483796 | A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency |
Q38676858 | Bendamustine associated immune suppression and infections during therapy of hematological malignancies |
Q38979354 | Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials |
Q41257177 | Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study |
Q31056968 | Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. |
Q21198858 | Novel agents for chronic lymphocytic leukemia |
Q24186840 | Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis |
Q39180275 | The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia |
Search more.